・Dr. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor, remaining actively involved with CordenPharma
・Planned leadership transition builds on 12 years of significant growth and transformation under Dr. Quirmbach's leadership BASEL, Switzerland, Sept. 15, 2026 /PRNewswire/ -- CordenPharma, a leading global pharmaceutical CDMO, announced today the appointment of Dr. Jean-Luc Herbeaux as Chief Executive Officer, effective 1 October 2026, as the compa…READ FULL ARTICLE
